Muscle Invasive Bladder Cancer
24
3
6
5
Key Insights
Highlights
Success Rate
63% trial completion
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 47/100
12.5%
3 terminated out of 24 trials
62.5%
-24.0% vs benchmark
8%
2 trials in Phase 3/4
140%
7 of 5 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 5 completed trials
Clinical Trials (24)
Treatment Combination of Durvalumab, Tremelimumab and Enfortumab Vedotin or Durvalumab and Enfortumab Vedotin in Patients With Muscle Invasive Bladder Cancer Ineligible to Cisplatin or Who Refuse Cisplatin
Durvalumab+ Gemcitabine/Cisplatin (Neoadjuvant Treatment) and Durvalumab (Adjuvant Treatment) in Patients With MIBC
Radical CystEctomy or RaDio-chEMotherapy as Preferred Treatment for invasivE blaDder Cancer
Sample Collection for Ongoing Research and Product Evaluation Study
Open-Label, Randomised, Multi-Drug, Biomarker-Directed, Phase 1b Study in Pts w/ Muscle Invasive Bladder Cancer
Avelumab and Radiation in Muscle-Invasive Bladder Cancer
Effect of Neoadjuvant Chemotherapy on MRI Accuracy Before Cystectomy
Role of FDG-PET CT in the Management of Muscle Invasive Bladder Cancer
Pilot Study on Rutin Combined With Tislelizumab and GC (Gemcitabine and Cisplatin) as Neoadjuvant Therapy for Platinum-refractory Muscle-invasive Bladder Cancer
A Novel Pathway to Detect Muscle-invasive Bladder Cancer Based on Integrated Clinical Features and VI-RADS Score on MRI
Sasanlimab As Maintenance Treatment Based on Clinical Response to Neoadjuvant Treatment in Molecularly Categorized Muscle Invasive Bladder Cancer Patients
Clinical Performance Evaluation of the C2i Test
RC48 Combined With Toripalimab and Radiotherapy for Bladder Sparing Treatment in MIBC
Rucaparib in Patients With Locally Advanced or Metastatic Urothelial Carcinoma
To Better Understand the Most Important Factors for Patients When They Decide on the Type of Treatment They Receive for Muscle Invasive Bladder Cancer (MIBC).
Perioperative Tislelizumab Combined With Nab-Paclitaxel for Muscle-invasive Urothelial Bladder Carcinoma
A Feasibility Study of Durvalumab +/- Oleclumab as Neoadjuvant Therapy for Muscle-invasive Bladder Cancer (BLASST-2)
A Study to Evaluate the Safety and Efficacy of Oral APL-1202 in Combination With Tislelizumab Compared to Tislelizumab Alone as Neoadjuvant Therapy in Patients With Muscle Invasive Bladder Cancer
Neoadjuvant Dose Dense MVAC in MIBC and Locally Advanced Urothelial Carcinoma
BLASST-1 (Bladder Cancer Signal Seeking Trial): Nivolumab, Gemcitabine, and Cisplatin in Treatment of Muscle Invasive Bladder Cancer (MIBC) Undergoing Cystectomy